Comments on cost analysis of risperidone versus olanzapine.
Harpreet S
HS
Duggal
Gaurav
G
Gandotra
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000191:economics; D003365:Costs and Cost Analysis; D003431:Cross-Cultural Comparison; D016527:Drug Costs / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination; D017721:Hospital Costs / Q000706:statistics & numerical data; D006760:Hospitalization / Q000191:economics; D006801:Humans; D000077152:Olanzapine; D012107:Research Design / Q000592:standards; D012189:Retrospective Studies; D018967:Risperidone / Q000191:economics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D006113:United Kingdom; D014481:United States
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine